Achieve Life Sciences ACHV

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.01 (-0.16%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Achieve Life Sciences (ACHV)
    Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $3.14

    • Market Cap

      $107.98 Million

    • Price-Earnings Ratio

      -2.80

    • Total Outstanding Shares

      34.39 Million Shares

    • Total Employees

      22

    • Dividend

      No dividend

    • IPO Date

      October 12, 1995

    • SIC Description

      In Vitro & In Vivo Diagnostic Substances

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      22722 29th dr. se, Seattle, WA, 98021

    • Homepage

      https://www.achievelifesciences.com

    Historical Stock Splits

    If you bought 200 shares of ACHV before May 24, 2018, you'd have 1 share today.
    Execution DateSplit Amount
    July 31, 20201-for-20 (Reverse Split)
    May 24, 20181-for-10 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Investing Activities$-33.30 Million
    Net Cash Flow From Financing Activities$47.84 Million
    Net Cash Flow From Financing Activities, Continuing$47.84 Million
    Net Cash Flow, Continuing$-10.40 Million
    Net Cash Flow From Investing Activities, Continuing$-33.30 Million
    Net Cash Flow From Operating Activities$-24.95 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Income/Loss$-32.94 Million
    Preferred Stock Dividends And Other Adjustments$0
    Research and Development$17.64 Million
    Costs And Expenses$31.27 Million
    Net Income/Loss Attributable To Parent$-32.94 Million
    Income/Loss From Continuing Operations After Tax$-32.94 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$71,000
    Comprehensive Income/Loss Attributable To Parent$-32.87 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-32.87 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Assets$47.92 Million
    Equity Attributable To Noncontrolling Interest$0
    Liabilities And Equity$47.92 Million
    Liabilities$16.54 Million
    Noncurrent Liabilities$9.82 Million
    Wages$2.34 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ACHV from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.